News >

Wang Highlights Encouraging CAR T-Cell Activity in MCL

Jessica Hergert
Published: Monday, Dec 23, 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center

Michael Wang, MD

The multicenter phase II ZUMA-2 trial investigating the CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma (MCL) reported significant and durable responses, thus paving the way for the novel treatment to revolutionize the field, said Michael Wang, MD. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication